Background. The epothilones are a new class of microtubule-stabilizing drugs that exert potent antitumor activity against taxane-resistant and multidrug resistant cell lines. The most clinically advanced member of this class is the semisynthetic epothilone B derivative ixabepilone.
Purpose. This article reviews the preclinical and clinical data on ixabepilone in patients with locally advanced and metastatic breast cancer (MBC) and provides guidance for pharmacists on its optimal use. Data sources. PubMed and conference proceedings through August 2008.
Results. In preclinical studies, ixabepilone has demonstrated potent antitumor activity and low susceptibility to mechanisms that confer tumor resistance. Clinically meaningful benefits have been achieved with ixabepilone monotherapy in phase 2 trials of patients with MBC who have failed previous chemotherapies (anthracyclines, taxanes, or capecitabine). In a randomized, phase 3 trial, the combination of ixabepilone and capecitabine proved more effective than capecitabine alone after the failure of taxane and anthracycline regimens. At the recommended dose and schedule, the therapeutic ratio of ixabepilone is generally favorable, and its adverse effects (notably neutropenia and peripheral neuropathy) are generally manageable and reversible.
Conclusion. Ixabepilone represents an advance in the treatment of anthracycline - and taxane-pretreated MBC. Future studies will define its efficacy in combination with other drugs used in the treatment of MBC, as well as in other types of cancer. J Oncol Pharm Practice (2009) 15: 95—106.
Hamilton A., Hortobagyi G.Chemotherapy: what progress in the last 5 years?J Clin Oncol2005; 23: 1760-75.
2.
Carrick S., Parker S., Wilcken N. et al. Single agent versus combination chemotherapy for metastatic breast cancer (review). Cochrane Database Syst Rev2005; 2: CD003372.
3.
Colozza M., de Azambuja E., Personeni N. et al. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist2007; 12: 253-70.
4.
Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer . J Clin Oncol2005; 23: 792-99.
5.
Slamon DJ, Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med2001; 344: 783-92.
6.
Geyer CE, Forster J., Lindquist D. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med2006; 355: 2733-43.
7.
Bernard-Marty C., Cardoso F., Piccart MJFacts and controversies in systemic treatment of metastatic breast cancer. Oncologist2004 ; 9: 617-32.
8.
Longley DB, Johnston PGMolecular mechanisms of drug resistance. J Pathol2005; 205: 275-92.
9.
Perez EA, Lerzo G., Pivot X. et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol2007 ; 25: 3407-14.
10.
Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol1999 ; 17: 485-93.
11.
Fumoleau P. , Largillier R., Clippe C. et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer2004 ; 40: 536-42.
12.
Bollag DM, McQueney PA, Zhu J. et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res1995; 55: 2325-33.
13.
Gerth K., Bedorf N., Höfle G. et al. Epothilones A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo)1996; 49: 560-63.
14.
Bode CJ, Gupta Jr ML, Reiff EA et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry2002; 41: 3870-74.
15.
Nettles JH, Li H., Cornett B. et al. The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science2004; 305: 866-69.
16.
Goodin S., Kane MP, Rubin EHEpothilones: mechanism of action and biologic activity. J Clin Oncol2004; 22: 2015-25.
17.
Cortes J., Baselga J.Targeting the microtubules in breast cancer beyond taxanes: the epothilones . Oncologist2007; 12: 271-80.
18.
Fumoleau P. , Coudert B., Isambert N. et al. Novel tubule-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol2007; 18: v9-v15.
19.
Lee FY, Borzilleri R., Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res2001; 7: 1429-37.
20.
Kowalski RJ , Giannakakou P., Hamel E.Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J Biol Chem1997; 272: 2534-41.
21.
Altmann KH, Pfeiffer B., Arseniyadis S. et al. The chemistry and biology of epothilones-the wheel keeps turning . Chem Med Chem2007; 2: 396-423.
22.
Ixabepilone: Prescribing Information. Bristol-Myers Squibb , Princeton, NJ, October 2007.
23.
Rowinsky EK , Calvo E.Novel agents that target tublin and related elements. Semin Oncol2006; 33: 421-35.
24.
McDaid HM, Mani S., Shen HJ et al. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study . Clin Cancer Res2002 ; 8: 2035-43.
25.
Mani S., McDaid HM, Grossman A. et al. Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. Ann Oncol2007; 18: 190-95.
26.
Brooks TA, Minderman H., O'Loughlin KL et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther2003; 2: 1195-205.
27.
Burger H., Foekens JA, Look MP et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res2003; 9: 827-36.
28.
Gianni L.Anthracycline resistance: the problem and its current definition. Semin Oncol1997; 24: S10-11-S10-17.
29.
Bodey B., Bodey Jr B., Gröger AM et al. Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: clinical and therapeutic significance. Anticancer Res1997; 17: 1311-18.
30.
Kubota T., Furukawa T., Tanino H. et al. Resistant mechanisms of anthracyclines-pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues. Breast Cancer2001; 8: 333-38.
31.
Paradiso A. , Mangia A., Chiriatti A. et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer . Ann Oncol2005; 16: iv14-19.
32.
Hari M., Loganzo F., Annable T. et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of ß-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther2006; 5: 270-78.
33.
Wang Y., O'Brate A., Zhou W. et al. Resistance to microtubule-stabilizing drugs involves two events: ß-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle2005; 4: 1847-53.
34.
Roujier R., Rajan R., Wagner P. et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA2005 ; 102: 8315-20.
35.
Vansteenkiste J., Lara Jr PN, Le CT et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy . J Clin Oncol2007; 25: 3448-55.
36.
Burtness B., Goldwasser MA, Axelrod R. et al. A randomized phase II study of BMS-247550 (ixabepilone) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck. J Clin Oncol2006; 24 (abstract 5532).
37.
Rosenberg JE , Weinberg VK, Kelly WK et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer2007; 110: 556-63.
38.
Liu G., Wang W., Dipaola R. et al. A phase II study of a weekly schedule of BMS-247550 for patients with hormone-refractory prostate cancer: A trial of the Eastern Cooperative Oncology Group (E3803). J Clin Oncol2007; 24 (abstract 4618).
39.
Hussain M., Tangen CM, Lara Jr PN et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol2005 ; 23: 8724-29.
40.
Abraham J., Agrawal M., Bakke S. et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol2003; 21: 1866-73.
41.
ClinicalTrials.gov. National Library of Medicine, US National Institutes of Health. Available at: http://www.clinicaltrials.gov. Accessed December 6, 2007
42.
Lee FY, Camuso A., Castenada S. et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung cancer xenografts. J Clin Oncol2006; 24 (abstract 12017).
43.
Vahdat LT, Klimovsky J., Bunnell C.Phase I/II trial in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline: final safety data. J Clin Oncol2006; 24 (abstract 10528).
44.
Aghajanian C., Burris HA, 3rd, Jones S. et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol2007; 25: 1082-88.
45.
Beumer JH, Garner RC, Cohen MB et al. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs2007; 25: 327-34.
46.
Shimizu T., Yamamoto N., Yamada Y. et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol2007; 61: 751-88.
47.
Gadgeel SM, Wozniak A., Boinpally RR et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res2005; 11: 6233-39.
48.
Mani S., McDaid H., Hamilton A. et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res2004; 10: 1289-98.
49.
Roché H., Yelle L., Cognetti F. et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol2007; 25: 3415-20.
50.
Takimoto CH , Liu PY, Lenz H. et al. A phase I pharmacokinetic (PK) study of the epothilone B analogue, ixabepilone (BMS-247550) in patients (pts) with advanced malignancies and varying degrees of hepatic impairment. A SWOG Early Therapeutics Committee and NCI Organ Dysfunction Working Group trial. J Clin Oncol2006; 24 (abstract 2004).
51.
Goel S., Goldberg G., Iacono LC et al. Effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone. J Clin Oncol2006; 24 (abstract 2005).
52.
Denduluri N. , Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol2007; 25: 3421-27.
53.
Denduluri N. , Lee JJ, Walshe J. et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs2007; 25: 63-7.
54.
Thomas E., Tabernero J., Fornier M. et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol2007; 25: 3399-406.
55.
Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol2005; 23: 2726-34.
56.
Baselga J., Gianni L., Llombart A. et al. Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). In 28th Annual San Antonio Breast Cancer Symposium, December 8-11, 2005; San Antonio, TX. (abstract 305).
57.
Bunnell CA, Klimovsky J., Thomas E.Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J Clin Oncol2006; 24 (abstract 10511).
58.
Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol2007; 25: 5210-17.
59.
Jassem J., Li RK, Thomas E. et al. Ixabepilone plus capecitabine treatment in a first line setting in patients with metastatic breast cancer (MBC) resistant to anthracycline and taxane therapy: a subgroup analysis from a phase III study. In 14th Biennial Congress of the European Cancer Organization, September 23-27, 2007; Barcelona Spain.
60.
Rugo HS, Thomas ES, Lee RK et al. Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. In 30th Annual San Antonio Breast Cancer Symposium, December 13-16, 2007; San Antonio, TX. (abstract 6069).
61.
Miles D., von Minckwitz G., Seidman ADCombination versus sequential single-agent therapy in metastatic breast cancer . Oncologist2002; 7: 13-9.
62.
Hudis CASingle-agent vs combination therapy in advanced breast cancer: potential roles of capecitabine. Oncology (Williston Park)2002; 16: 13-6.
63.
Lee JJ, Low JA, Croarkin E. et al. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol2006; 24: 2084-91.
64.
Lee JJ, Swain SMDevelopment of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol2005; 32: S22-S26.
65.
Wickham R.Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin J Oncol Nurs2007; 11: 361-76.
66.
Markman M.Management of toxicities associated with the administration of taxanes . Expert Opin Drug Saf2003; 2: 141-46.
